Mustbio is an immuno-oncology company
dedicated to developing first-in-class and best-in-class
multi-specific antibodies for cancer treatment.
We leverage our innovative platforms, BICSTA™ and STARKINE™, to develop tumor-directed multi-specific antibodies
with broader therapeutic potential. Mustbio is committed to creating next-generation immuno-oncology therapies,
ensuring that patients receive safer and more effective treatment options. Through continuous research and development,
and active collaboration with global partners, we aim to revolutionize cancer care and improve patient outcomes.
Our Mission
Our mission is to lead the development of next-generation immuno-oncology drugs that offer groundbreaking treatments for cancer patients worldwide. We are dedicated to pushing the boundaries of current treatment practices, leveraging the body's immune system to fight cancer with unprecedented precision and effectiveness.
Our Triple-I Principle
Driven by sheer commitment to integrity, innovation, and integration, we aim to cultivate an environment conducive to creating treatments that truly enhance the lives of patients.
Integrity
Ensure fairness and honesty
Innovation
Continuously search for and develop
groundbreaking solutions
Integration
Foster collaboration internally
and externally to achieve shared success
